The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma

This publication has 11 references indexed in Scilit:

• Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced Cancer
  JNCI Journal of the National Cancer Institute, 1993
• Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses.
  Journal of Clinical Oncology, 1993
• Thrombocytopenia during immunotherapy with interleukin-2 by constant infusion
  The American Journal of Medicine, 1990
• Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
  Annals of Surgery, 1989
• Induction of Interferon‐β₂/Interleukin‐6 (IL‐6) by Cytokine Administration and Detection of Circulating Interleukin‐6 in the Tumor‐bearing State
  Annals of the New York Academy of Sciences, 1989
• Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma
  New England Journal of Medicine, 1988
• Colonic perforation: An unusual complication of therapy with high-dose lnterleukin-2
  Cancer, 1988
• The Neuropsychiatric Effects of Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells
  Annals of Internal Medicine, 1987
• Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients
  Blood, 1987
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987